New Formulation of Roche’s Perjeta-Herceptin Combo for HER2-Positive Breast Cancer Up for Possible FDA Approval
News
The U.S. Food and Drug Administration (FDA) will review Roche’s application seeking regulatory approval for a new formulation — given as a subcutaneous, or under-the-skin injection — of the fixed-dose ... Read more